"I am deeply honored to have been selected to help launch this important new special section of the Journal of Translational Medicine," Mr. Silva said. "Today, most regenerative medicine research remains confined to the bench rather than the bedside. But if our cell-based therapy development progress at BioRestorative, as well as that at several other companies, is any indication, it may not be long before the full clinical potential of the field is realized. I am energized by this unique opportunity to wor ...

- New journal section will focus on emerging and translation work in the field of regenerative medicine - "We are excited to expand the journal's focus on regenerative medicine and are thrilled to have found someone with Francisco's demonstrated research excellence, pioneering clinical experience, and ability to serve as a respected ambassador to become our newest Section Editor," said the Journal of Translational Medicine's Editor-in-Chief, Francesco Marincola, MD. Earlier in his career, in 2008, Mr. Silva ...

– Expanding intellectual property estate expected to help drive ThermoStem® licensing opportunities – Previously published peer-reviewed preclinical data from a study conducted in collaboration with the University of Utah School of Medicine ("UUSOM") demonstrated a clonogenic population of metabolically active brown adipose tissue ("BAT") stem cells residing in adult humans that: (i) can be expanded in vitro; (ii) exhibit multilineage differentiation potential (osteogenetic, chondrogenic and adipogenic); an ...

MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, announced that it has received notice from the Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) in connection with the filing of its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 with the Securities and Exchange Commission. Summary First Quar ...

- Potential license partner is a leading commercial stage regenerative medicine company – No assurances can be given that a license agreement will be entered into whether on commercially reasonable terms or otherwise. The Company does not intend to make any further announcements with regard to the license unless and until an agreement is entered into. • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal ...

BADSCs with brown adipogenic potential would represent an exciting new modality for the treatment of obesity and related metabolic disorders. To explore this possibility, BioRestorative developed a 3D Porous Extracellular Matrix-Derived Scaffold for effective cell delivery. Data obtained in high-fat fed NOD-SCID mice transplanted with differentiated BADSCs supported by the 3D scaffold showed significant reductions in weight, triglyceride and blood glucose levels compared to saline-only injected controls. No ...

This quarterly report represents an earnings surprise of -3.92%. A quarter ago, it was expected that this company would post a loss of $0.65 per share when it actually produced a loss of $0.57, delivering a surprise of 12.31%. Biorestorative Therapies, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.04 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 16.67%. This compares to year-ago revenues of $0.03 million. The company has t ...

For the Three Months Ended March 31, 2023 Series B Convertible Additional Preferred Stock Common Stock Paid-In Accumulated Shares Amount Shares Amount Capital Deficit Total | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------|-----------|------------|-----------|-------|-------|--------------|----------------|---------------| | Return and cancellation of shares in lieu of payroll tax \nwithholding | - | - | (10,058) ...

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference. About BioRestorative Therapies, Inc. BioRestorative Therapies, ...

MELVILLE, NY., June 04, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Global Healthcare Conference being held June 5-6, 2024 at the Marriot Marquis in New York. Management will also be available for one-on-one investor meetings during the conference. About BioRestorative Therapies, Inc. BioRestorative Therapies, ...